Fusion Pharmaceuticals Inc. has made a significant move in the oncology sphere announcing its exclusive worldwide license agreement with Heidelberg University and Euratom, represented by the European Commission's Joint Research Centre. 

This agreement marks a pivotal step in Fusion's journey toward developing next-generation radiopharmaceuticals as precision medicines.

The license grants Fusion exclusive rights to utilize, develop, manufacture, and commercialize compounds covered by the patent, notably including 225Ac-PSMA I&T ('FPI-2265'), aimed at treating prostate-specific membrane antigen (PSMA)-expressing cancers. This move underscores Fusion's commitment to advancing cutting-edge treatments for challenging cancer types.

Fusion's President and Chief Business Officer, Mohit Rawat, expressed enthusiasm about the partnership, emphasizing the potential of FPI-2265 as the most advanced actinium-based PSMA-targeted radiotherapy currently in development. "With Fusion's expertise in the development and manufacturing of alpha-emitting radiopharmaceuticals, an operational radiopharmaceutical manufacturing facility, and our advantageous actinium supply, we are well positioned to execute this program. We look forward to providing updates as we reach anticipated upcoming milestones in 2024, including data from the TATCIST study in April and the initiation of our Phase 2/3 registrational study in the second quarter," he said.

Anticipation mounts for Fusion's anticipated milestones in 2024, including data from the TATCIST study in April and the initiation of a Phase 2/3 registrational study in the second quarter. The company's strategic alignment with the US Food and Drug Administration on the Phase 2/3 protocol for FPI-2265 further solidifies its trajectory. The updated development plan includes a Phase 2 dose optimization lead-in, expected to complete enrollment by the end of 2024, followed by a Phase 3 registrational trial slated for 2025.

Financial terms of the license agreement stipulate that Fusion will pay the Licensors an upfront fee of EUR 1.0 million, alongside regulatory milestones upon potential approval, and low single-digit royalties on future net sales of applicable products. This financial arrangement underscores Fusion's commitment to fair and collaborative partnerships in driving forward innovative cancer therapies.

With this exclusive license secured, Fusion Pharmaceuticals is poised to make significant strides in the fight against prostate cancer, bringing hope to patients and further solidifying its position as a leader in precision oncology.